INOSITEC

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company's lead programs address vascular and renal calcification disorders, including orphan indications. Inositec was founded in December 2015 as a spin-off of ETH Zurich.

Also known as: Inositec AG

Primary location: Zurich Switzerland